

Life Sciences 71 (2002) 2015-2023

Life Sciences

www.elsevier.com/locate/lifescie

Fumonisin B₁ alters sphingolipid metabolism and tumor necrosis factor α expression in heart and lung of mice

Quanren He, Neetesh Bhandari, Raghubir P. Sharma*

Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602-7389, USA

Received 23 October 2001; accepted 10 May 2002

Abstract

Fumonisin B₁ (FB₁), produced by Fusarium verticillioides, is a common contaminant in foods and feeds. Increase in tissue free sphingoid bases resulting from the inhibition of ceramide synthase is a biomarker of fumonisin exposure. Tumor necrosis factor α (TNF α) is induced in liver in response to FB₁ treatment. This study determined whether fumonisin B_1 caused increases in free sphingoid bases and altered the expression of TNF α in heart and lung, organs that are not targets of FB₁ toxicity, of male and female mice treated with 5-daily subcutaneous injection of 2.25 mg/kg FB₁. A significant increase in free sphingoid bases was observed in both heart and lung of FB₁-exposed mice. The magnitude of increases in free sphingoid bases in both organs of female mice was much higher than that in males. The expression of $TNF\alpha$ was increased by FB_1 treatment in the lung of male mice and in the heart of female mice, whereas the expression of interferon γ was unaltered. Results suggest that both sphingolipid accumulation and $TNF\alpha$ induction are observed in the tissues of mice that are not associated with FB₁ toxicity.

© 2002 Elsevier Science Inc. All rights reserved.

Keywords: Fumonisin; Heart; Lung; Sphingolipid; Tumor necrosis factor α

Introduction

Fumonisins are a group of structurally related mycotoxins produced by Fusarium verticillioides (formerly F. moniliforme) and F. proliferatum, commonly found on corn [1]. Fumonisin B₁ (FB₁) is the

0024-3205/02/\$ - see front matter © 2002 Elsevier Science Inc. All rights reserved.

PII: S0024-3205(02)01988-4

Corresponding author. Tel.: +1-706-542-2788; fax: +1-706-542-3015. E-mail address: rpsharma@vet.uga.edu (R.P. Sharma).

most abundant fumonisin in naturally contaminated foods and feeds. Fumonisins cause equine leukoencephalomalacia and porcine pulmonary edema [2]. It is carcinogenic in rats [3] and mice [4]. Epidemiological surveys reported that there were significantly higher levels of FB₁ in corn samples from high incidence areas of esophageal cancer in Transkei, South Africa than in corresponding samples from low incidence areas [2]; a relationship between fumonisin and primary liver cancer in China has also been suggested [5]. Fumonisin B₁ induces apoptosis and necrosis in many types of cultured cells [6-8] and in liver and kidney in rodents [9,10].

Fumonisin B₁ is structurally similar to sphinganine, and is a potent inhibitor of ceramide synthase (sphinganine and sphingosine-*N*-acyl transferase), a key enzyme responsible for acylation of sphinganine in the *de novo* synthesis of sphingolipid and the reacylation of sphingosine [11,12]. The inhibition of ceramide synthase by FB₁ results in the accumulation of intracellular free sphinganine and sphingosine, and decrease of more complex sphingolipids [8,13]. Studies in pig renal epithelial cells, colonic cells, and human keratinocytes have shown that FB₁-induced apoptosis and necrosis are sphinganine-dependent [8,14,15]. It has been reported that there is a close correlation between FB₁-induced hepatopathy and nephropathy and the disruption of sphingolipid metabolism [13,16].

Previous studies have shown a potential role of tumor necrosis factor α (TNF α) in FB₁ toxicity [9,17–21]. The TNF α activity and expression of TNF α mRNA were increased in FB₁-treated mice [9,17,18,22]. The TNF α pathway was activated in cells treated with FB₁ [19–21]. Other inflammatory cytokines including interferon (IFN) γ were increased in the liver of mice after FB₁ treatment [22].

Lung and heart are the target organs of fumonisins in pigs [23,24]. The National Toxicology Program conducted a 2-year feeding study using rats and mice; the oncogenic and pathologic effects of FB₁ were limited to male rat kidney and female mouse liver [4]. Accumulation of *de novo* synthesized sphinganine is an early biochemical change in liver and kidney in response to FB₁ treatment at doses below those that produce morphological evidence of injury, and these increases in tissue free sphinganine occurs before evident damage can be detected [25]. Moreover, it has been reported that free sphinganine and sphingosine increased in heart and serum of milk-fed calves after FB₁ treatment (intravenous, 1 mg/kg/day for 7 days), but no cardiovascular damage was detected [26], although the degree of increases in free sphingoid bases was greater in these calves than in pigs associated with myocardial dysfunction [23]. It is of interest to investigate whether FB₁ would influence sphingolipid metabolism in heart and lung, which are not principal target organs in either sex of mice. In the current study, exposure of male or female BALB/c mice to 2.25 mg/kg/day FB₁ for 5 consecutive days resulted in accumulation of free sphingoid bases as well as increase in the expression of TNF α mRNA in both heart and lungs. Results suggest that the organ specificity to FB₁ may depend on other intrinsic factors in addition to sphingoid bases accumulation and cytokine modulation.

Materials and method

Animals and treatment

Male and female BALB/c mice, 7-8 weeks old, were obtained from Harlan Laboratories (Indianapolis, IN). The animals were acclimated in the University of Georgia Animal Resources facility for one

Download English Version:

https://daneshyari.com/en/article/2555272

Download Persian Version:

https://daneshyari.com/article/2555272

Daneshyari.com